The inhibitor of apoptosis protein family has been characterized over the past 5 years, initially in baculovirus and more recently in metazoans. The IAPs are a widely expressed gene family of apoptotic inhibitors from both phylogenic and physiologic points of view. The diversity of triggers against which the IAPs suppress apoptosis is greater than that observed for any other family of apoptotic inhibitors including the bcl-2 family. The central mechanisms of IAP apoptotic suppression appear to be through direct caspase and pro-caspase inhibition (primarily caspase 3 and 7) and modulation of and by the transcription factor NF-κB. Although evidence for a direct oncogenic role for the IAPs has yet to be delineated, a number of lines of evidence point towards this class of protein playing a role in oncogenesis. The strongest evidence for IAP involvement in cancer is seen in the IAP called survivin. Although not observed in adult differentiated tissue, survivin is present in most transformed cell lines and cancers tested to date. Survivin has been shown to inhibit caspase directly and apoptosis in general, moreover survivin protein levels correlate inversely with 5 year survival rates in colorectal cancer. Recent data has also implicated survivin in cell cycle control. The second line of evidence for IAP involvement in cancer comes from their emerging role as mediators and regulators of the anti-apoptotic activity of v-Rel and NF-κB transcription factor families. The IAPs have been shown to be induced by NF-κB or v-Rel in multiple cell lines and conversely, HIAP1 and HIAP2 have been shown to activate NF-κB possibly forming a positive feed-back loop. Overall a picture consistent with an IAP role in tumour progression rather than tumour initiation is emerging making the IAPs an attractive therapeutic target.

Affiliations

1. Apoptogen Inc, Suite R306, CHEO Research Institute, 401 Smyth Road, Ottawa, Ontario, Canada, K1H 8L1

   • Eric C LaCasse
   • , Stephen Baird
   • , Robert G Korneluk
   •  & Alex E MacKenzie

2. Department of Pediatrics, University of Ottawa, Ontario, Canada

   • Stephen Baird
   • , Robert G Korneluk
   •  & Alex E MacKenzie

3. The Solange Gauthier Karsh Molecular Genetics Laboratory, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada, K1H 8L1

   • Stephen Baird
   • , Robert G Korneluk
   •  & Alex E MacKenzie

Corresponding author

Correspondence to Alex E MacKenzie.

To obtain permission to re-use content from this article visit RightsLink.

Publication history

DOI

https://doi.org/10.1038/sj.onc.1202569